Short Answer
What Is Microdosing Tirzepatide?
Microdosing tirzepatide means taking a weekly dose smaller than the maintenance doses the FDA approved, most often at or below the 2.5 mg starting dose. The term comes from patients and clinics, not from a regulator or a trial protocol. There is no official threshold, which is why one clinic's microdose is another clinic's starting dose.
Tirzepatide is a dual GIP and GLP-1 receptor agonist sold as Zepbound, approved for weight reduction and long-term weight maintenance and for moderate to severe obstructive sleep apnea in adults with obesity, and as Mounjaro for type 2 diabetes. Using it below the approved maintenance range is off-label prescribing. Off-label use is legal and common in medicine, and it means the specific dose has not been reviewed by the FDA for that purpose.
Protocol Health prescribes tirzepatide as part of physician-supervised medical weight loss, so there is a commercial interest in this topic. That is the reason the article is built on the drug label and the published trials rather than on what the clinic would prefer to be true.
Book a medical weight loss consultThe Label
What the Tirzepatide Label Says About Dose
The approved dosing for tirzepatide is written down, and it is short. The Zepbound prescribing information states that the recommended starting dosage is 2.5 mg injected subcutaneously once weekly for 4 weeks, that the dosage may then be increased in 2.5 mg increments after at least 4 weeks on the current dose, and that the recommended maintenance dosage is 5 mg, 10 mg or 15 mg once weekly. The maximum is 15 mg once weekly.
One sentence in that label does most of the work in any microdosing conversation. The label states plainly that "the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage." A weekly dose of 2.5 mg held indefinitely is therefore already outside the approved regimen, and the sub-2.5 mg amounts that circulate as microdoses are fractions of a starting dose that was never meant to be held at all.
The label is not silent on going lower, either. It instructs that if a patient does not tolerate a maintenance dosage, the prescriber should consider a lower maintenance dosage. That is the sanctioned route to a smaller dose: a clinical decision made for tolerability, inside a range that was studied, by the person holding the prescription pad.
The Evidence
Does Microdosing Tirzepatide Work?
No randomized trial has tested microdosing tirzepatide as a weight-management strategy, so the honest answer is that nobody knows how well it works for that purpose. What exists is a dose-response curve from the pivotal obesity trial, one phase 2 diabetes trial that happened to randomize a dose below the starting dose, and a clear floor beneath which weight outcomes in obesity were never measured.
In SURMOUNT-1, published in the New England Journal of Medicine in 2022, 2,539 adults with obesity or with overweight plus a weight-related complication were randomized to tirzepatide 5 mg, 10 mg or 15 mg weekly or to placebo for 72 weeks. Mean weight change was -15.0% at 5 mg, -19.5% at 10 mg, -20.9% at 15 mg and -3.1% on placebo.
The floor nobody measured
Five milligrams weekly is the lowest dose that trial measured as a maintenance dose, and the lowest the label approves for one. Every dose below it sits in a gap in the obesity evidence, with one exception worth knowing about. The phase 2 trial that first tested tirzepatide, published in The Lancet in 2018, randomized a 1 mg weekly arm in type 2 diabetes over 26 weeks. That is below the 2.5 mg starting dose, so it is the only randomized look beneath it, and the result is sobering for anyone hoping a microdose does most of the work: average weight change was 0.9 kg at 1 mg, against 11.3 kg at 15 mg and 0.4 kg on placebo. It was not an obesity trial and it was not a maintenance study, but on weight the lowest dose landed close to placebo. In SURMOUNT-1 the gastrointestinal adverse events occurred primarily during dose escalation, which spans the 2.5 mg step and the steps above it rather than the 2.5 mg step alone. The trial did not report a weight outcome for the initiation step, and what a sub-5 mg dose delivers over a year in obesity has not been measured.
That gap is documented in the literature itself. A 2025 letter in Diabetes Care on the microdosing question notes that the practice "is not currently included in clinical guidelines, and no randomized controlled trials support microdosing." Its author describes a strategy that emerged from patients and from drug shortages rather than from evidence, and still treats it as potentially useful in selected situations.
Both things are true at once. The absence of trial data is not proof that a smaller dose fails, and enthusiasm from clinics is not proof that it works. Anyone quoting a percentage for microdosing results is quoting something other than a trial.
The Chart
Is There a Microdosing Tirzepatide Chart or Schedule?
There is no validated microdosing tirzepatide chart. The only published, regulator-reviewed schedule for tirzepatide is the label's escalation, and it does not contain a microdose. The charts circulating in forums and on clinic websites are conventions somebody wrote down, not outputs of a trial or a guideline.
A table makes the gap visible.
| Regimen | What it is | Evidence behind it |
|---|---|---|
| Label escalation | 2.5 mg weekly for 4 weeks, then increases of 2.5 mg no sooner than every 4 weeks | FDA-reviewed; the regimen used in the SURMOUNT program |
| Approved maintenance | 5 mg, 10 mg or 15 mg once weekly; 15 mg is the maximum | Randomized data at all three doses over 72 weeks |
| Lower maintenance for tolerability | A prescriber steps a patient down within the approved range | Explicitly contemplated by the label |
| "Microdosing" charts online | Weekly amounts at or below 2.5 mg, sometimes expressed in syringe units | No randomized trials; not in any clinical guideline |
The unit charts deserve a separate warning. Compounded tirzepatide arrives as a vial at a concentration the pharmacy chose, so a dose written in "units" is meaningless without that concentration. The same 10 units can be a fraction of a milligram at one pharmacy and several milligrams at another. Converting a chart between vials is arithmetic performed on a prescription medicine, and it is a documented source of error: a poison control center case series in the Journal of the American Pharmacists Association recorded administration errors with compounded semaglutide, where patients and even health professionals miscalculated the volume to draw. A prescriber sets the dose, documents the concentration, and adjusts it against weight, labs and tolerance.
Why People Ask
Why People Ask About Microdosing Tirzepatide
Four motives come up repeatedly in clinic, and they are not equally well supported.
- Side effects. Nausea, constipation and reflux cluster during escalation, so a smaller dose is an intuitive response. The label already offers a sanctioned version of this: a lower maintenance dosage chosen for tolerability.
- Cost. A smaller dose stretches a vial further. This is a real motive and a poor clinical input, because the question of whether a dose works is separate from whether it is cheap.
- Maintenance after a goal weight. The most common reason, and the one with actual randomized evidence pointing the other way. See the next section.
- Metabolic and hormonal effects at low doses, including interest around perimenopause and inflammation. Mechanistically plausible, currently unproven in humans at microdoses, and the place where marketing runs furthest ahead of data.
A fifth reason is worth naming: some people want to be on a GLP-1 medicine without being the kind of person who is on a GLP-1 medicine. That is a human motive rather than a clinical one, and it is better discussed with a prescriber than resolved alone with a syringe.
Maintenance
Microdosing Tirzepatide for Maintenance: What the Withdrawal Trial Showed
Using a reduced dose of tirzepatide to hold weight loss is the single most common microdosing question, and it is the one place where randomized evidence exists. The evidence does not test a microdose. It tests whether stopping matters, and it does.
SURMOUNT-4, published in JAMA in 2024, enrolled 783 adults with obesity or overweight without diabetes in a 36-week open-label lead-in on the maximum tolerated dose of tirzepatide, either 10 mg or 15 mg weekly. Mean weight reduction over that lead-in was 20.9%. At week 36, 670 participants were randomized to continue tirzepatide or switch to placebo for 52 weeks.
From week 36 to week 88, the group that continued lost a further 5.5% on average, while the placebo group regained 14.0%. At week 88, 89.5% of those continuing tirzepatide had kept at least 80% of the weight lost during the lead-in, against 16.6% of those switched to placebo.
What that does and does not prove
The maintenance arm stayed on 10 mg or 15 mg weekly. It was not stepped down to a microdose. So the only randomized maintenance evidence for tirzepatide supports continuing a full maintenance dose, and it says nothing at all about whether a fraction of that dose would have held the result. Treating SURMOUNT-4 as support for microdosing reverses what it measured.
What the trial does establish is that the medication is doing continuous work. Weight regain on withdrawal is the expected physiology of obesity treatment rather than a personal failure, which is also the frame we use for a weight loss plateau.
Compounded
Microdosing and Compounded Tirzepatide
Most microdosing of tirzepatide happens with compounded product, because a multi-dose vial can be drawn in any amount while a brand pen delivers fixed doses. That convenience is also where the risk concentrates.
Compounded tirzepatide is not FDA-approved. It was not the product studied in SURMOUNT-1 or SURMOUNT-4, so the trial percentages above describe the brand medication and do not transfer to a compounded vial. The American Diabetes Association's 2025 statement on compounded GLP-1 and dual GIP/GLP-1 receptor agonists describes compounded formulations that bypass regulatory measures as raising safety, quality and efficacy concerns. Our guide to compounded versus brand-name GLP-1 medications covers the distinction in full.
Three questions are worth putting to any clinic offering a microdosing program: which state-licensed pharmacy prepares the vial, what concentration it is supplied at, and who calculates and documents the dose. A program that answers those three in writing is doing medicine. A program that sends a chart and a vial is doing something else.
Side Effects
Microdosing Tirzepatide Side Effects and Who Should Avoid It
A smaller dose of tirzepatide is generally expected to produce fewer gastrointestinal side effects, which is why the label's escalation schedule exists at all: it instructs prescribers to step the dose up gradually to reduce the risk of gastrointestinal adverse reactions. Side effects below the 2.5 mg starting dose have been measured in only one randomized setting, that phase 2 diabetes trial, where gastrointestinal events were reported in 23.1% of the 1 mg arm against 9.8% on placebo and rose with every dose step above it. No obesity trial has measured them below 5 mg weekly, so the size of that difference at a microdose in weight management is not known. A smaller dose does not create a different drug. In the SURMOUNT trials the most frequent adverse events were gastrointestinal, mostly mild to moderate, and most concentrated during dose escalation.
The serious cautions travel with the molecule rather than the amount. Tirzepatide carries a boxed warning for thyroid C-cell tumors seen in rodents and is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Pancreatitis, gallbladder disease, and interactions with insulin or sulfonylureas are evaluated before a prescription, not after.
Muscle is the other consideration a low dose does not solve. Any effective weight loss includes some lean mass, which is why protein intake, resistance training and body composition tracking belong in the plan at every dose. Our guide to GLP-1 therapy and muscle loss sets out what the trials measured. If you experience severe or persistent abdominal pain, signs of dehydration, or other concerning symptoms, contact a clinician promptly.
Our Approach
How Protocol Health Handles a Microdosing Request
Protocol Health is a physician-led practice that sees patients in person in Scarsdale, NY, and by telehealth across NY, NJ, CT, FL and CA. A microdosing tirzepatide request is treated as a dosing conversation rather than a product order: history, medication list, contraindications and baseline labs first, then a dose the prescriber selects and documents, then review against your response. The clinic prescribes tirzepatide and has a commercial interest in that decision, which is why the dose is a clinician's call and never a chart handed to a patient.
Microdosing tirzepatide is a term for using the medicine below its approved maintenance range. No randomized trial supports it, no guideline describes it, the lowest dose with obesity trial evidence behind it is 5 mg weekly, and the only randomized maintenance data came from continuing a full dose rather than reducing one. A lower dose for tolerability is a legitimate clinical move the label itself anticipates. A dose copied from a chart is not. This article is educational and not a substitute for individualized medical advice; suitability, dose and monitoring are decided with a qualified clinician who knows your full picture.
FAQ
Frequently Asked Questions
What is considered microdosing tirzepatide?
There is no official definition. In practice the term describes a weekly dose below the approved maintenance range of 5 mg, 10 mg or 15 mg, usually at or under the 2.5 mg starting dose. Because no trial or guideline defines the threshold, the same amount can be called a microdose at one clinic and a starting dose at another.
Is there a microdosing tirzepatide chart?
Not a validated one. The only regulator-reviewed schedule is the Zepbound label's escalation: 2.5 mg once weekly for 4 weeks, then increases of 2.5 mg no sooner than every 4 weeks, to a maintenance dose of 5 mg, 10 mg or 15 mg. Charts circulating online are conventions rather than trial outputs, and unit-based charts are unsafe to transfer between vials of different concentrations.
Does microdosing tirzepatide work for weight loss?
No randomized trial has measured it, so there is no reliable figure. The lowest dose studied as a maintenance dose in SURMOUNT-1 was 5 mg weekly, which produced a mean 15.0% weight reduction over 72 weeks against 3.1% on placebo. Results below that dose are anecdotal, and no outcome is guaranteed at any dose.
Is 2.5 mg of tirzepatide enough to lose weight?
No trial has reported a weight result for the 2.5 mg step, and the Zepbound label states that the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage. Holding it long term is off-label and has not been tested in a randomized trial. Whether it suits you is a prescriber's judgment.
How quickly does microdosing tirzepatide work?
Appetite changes are often noticed within the first weeks at any dose, because the effect on satiety begins early. Weight change accumulates far more slowly, and the SURMOUNT trials measured their primary results at 72 weeks. No published timeline exists specifically for microdoses.
Is microdosing tirzepatide safe?
A smaller dose generally means fewer gastrointestinal side effects, but it does not change the drug's contraindications. Tirzepatide carries a boxed warning for thyroid C-cell tumors seen in rodents and is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2. Safety also depends on the source: compounded tirzepatide is not FDA-approved.
Can you microdose tirzepatide for maintenance after reaching your goal?
Some clinicians reduce the dose for maintenance, which the label contemplates for tolerability within the approved range. The randomized evidence does not test a microdose: in SURMOUNT-4 the maintenance arm continued at 10 mg or 15 mg weekly, and those switched to placebo saw their body weight increase by a mean of 14.0% over the following 52 weeks. Any step down is a physician-directed decision.
Explore
Related at Protocol Health
Book a medical weight loss consultThis article is educational and is not medical advice. It does not diagnose, prevent, treat or cure any condition. Talk with a licensed clinician about your own situation.